Tremfya and Remicade take very different mechanistic approaches to moderate-to-severe ulcerative colitis. Remicade is the original anti-TNF for UC, with an efficacy record stretching back to ACT-1 and ACT-2 in the mid-2000s. Tremfya is an IL-23 p19-selective biologic approved for UC in September 2024 based on the QUASAR and ASTRO trials, offering both IV and fully subcutaneous induction pathways. UC patients commonly weigh these two drugs when choosing a first biologic or switching after loss of response. This guide walks through the tremfya vs remicade ulcerative colitis decision.
IL-23 p19 vs Anti-TNF Mechanism
Remicade (infliximab) is a chimeric monoclonal antibody that binds TNF-alpha, a cytokine that drives inflammation throughout the body and in the colon. Tremfya (guselkumab) binds the p19 subunit of interleukin-23, selectively blocking IL-23 signaling. IL-23 is a central driver of Th17-mediated inflammation in UC. The guselkumab vs infliximab UC distinction shapes efficacy timing, safety, and long-term convenience. Remicade's broader TNF blockade delivers rapid systemic anti-inflammatory effects. Tremfya's narrower IL-23 targeting produces strong efficacy with a cleaner infection profile and preserves IL-12 signaling for immune surveillance.
QUASAR and ASTRO: Tremfya UC Evidence
QUASAR was the pivotal phase 3 induction and maintenance trial of guselkumab in UC, including biologic-naive and biologic-experienced patients. At week 12, 23% of guselkumab patients achieved clinical remission compared with 8% on placebo, with endoscopic improvement also significantly better. Maintenance through week 44 showed sustained remission in patients who continued guselkumab versus those who switched to placebo. ASTRO specifically evaluated fully subcutaneous induction for guselkumab in UC, demonstrating that patients could skip IV induction entirely and still achieve meaningful response. Remicade's UC efficacy rests on ACT-1 and ACT-2, which established infliximab as one of the first effective UC biologics.
Efficacy Comparison
No head-to-head trial has compared Tremfya with Remicade in UC. Indirect comparisons from network meta-analyses suggest Tremfya produces similar clinical remission rates in biologic-naive patients. For anti-TNF experienced UC patients who have lost response to Remicade, Tremfya's p19 selectivity offers a meaningful mechanism switch that typically delivers better outcomes than a second anti-TNF. Remicade retains strong induction data, particularly for patients with acute severe UC who need rapid response. Tremfya's maintenance data from QUASAR showed durable remission through week 44, with real-world follow-up ongoing.
Onset of Action
Remicade works fast in UC. Many patients report symptom improvement within the first two weeks of induction, with full response evident by week 8. Tremfya's UC onset produces meaningful response by week 12 based on QUASAR. For UC patients with severe, active disease who need rapid control (including those hospitalized with acute severe UC), Remicade's faster action often matters clinically. For patients in less acute states or those weighing long-term administration and safety, Tremfya's response trajectory is generally acceptable given the other advantages, and the ASTRO-supported SC induction option allows treatment to begin without infusion center visits.
Safety Profiles
Remicade carries anti-TNF class risks including serious infections, reactivation of latent TB or hepatitis B, and a small increase in lymphoma risk. Long-term IBD registry data consistently shows higher hospitalization rates for serious infection on infliximab compared with IL-23 pathway biologics. Tremfya's UC safety data from QUASAR and ASTRO has been favorable, consistent with its broader psoriasis and psoriatic arthritis experience, with lower systemic infection rates than anti-TNFs. For tremfya vs remicade side effects, UC patients with infection concerns, cancer history, or other risk factors for immunosuppression complications often find Tremfya's narrower mechanism more reassuring. Both drugs require TB and hepatitis B screening before starting.
Administration and Dosing Flexibility
Remicade uses three IV induction doses at weeks 0, 2, and 6, followed by maintenance infusions every 8 weeks at 5 mg/kg for UC, with dose escalation to 10 mg/kg or interval shortening available if response wanes, per Janssen's Remicade information. Remicade requires lifelong infusions. Tremfya offers flexible UC administration. Patients can choose IV induction (200 mg at weeks 0, 4, and 8) or fully subcutaneous induction (400 mg at weeks 0, 4, and 8) based on preference and access, per the QUASAR and ASTRO programs. Maintenance is 100 mg SC every 8 weeks or 200 mg SC every 4 weeks. For UC patients who want to minimize long-term infusion time, Tremfya's SC maintenance is a meaningful practical advantage.
Switching From Remicade to Tremfya
UC patients who lose response to Remicade often consider a mechanism switch rather than cycling to a second anti-TNF. QUASAR included biologic-experienced patients and showed Tremfya's efficacy in this population. The tremfya after remicade UC transition generally does not require a lengthy washout, though timing depends on residual Remicade levels, antidrug antibodies, and individual patient factors. Your GI will weigh these alongside disease severity when planning the switch.
Cost and Access
Remicade has extensive biosimilar competition. Inflectra (infliximab-dyyb) and Renflexis (infliximab-abda) are widely available and often preferred on insurance formularies, which significantly lowers acquisition costs. Tremfya has no biosimilar and is priced as a branded biologic. For UC patients where insurance strongly favors a low-cost infliximab biosimilar, Remicade (or its biosimilar) may be the most accessible option. For patients whose plans cover Tremfya and prioritize the IL-23 mechanism or SC induction flexibility, manufacturer copay assistance programs can help bridge cost gaps for commercially insured patients.
Choosing With Your GI
For a UC patient deciding between Tremfya and Remicade, Remicade tends to win on induction speed, dose escalation flexibility, and biosimilar cost savings. Tremfya tends to win on long-term safety, SC maintenance convenience, unique SC-only induction via ASTRO, and performance in anti-TNF experienced patients. Ask your GI how response will be measured after induction, what to do if symptoms persist, whether therapeutic drug monitoring will be used, and how your insurance handles infliximab biosimilars versus branded IL-23 biologics. A log of stool frequency, urgency, blood, and any new extraintestinal symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.